Search

There is no standard of care for unresectable cutaneous squamous cell carcinoma (cSCC). Chemotherapy, alone or combined with radiotherapy, is commonly used mostly as palliative treatment; moreover, its poor safety profile limits its use most of the time, especially in elderly patients. Thus, alternative options are needed. Targeted molecular inhibitors, such as the epidermal growth factor receptor inhibitor cetuximab, seem promising, but data are limited. We retrospectively evaluated clinical outcomes of cetuximab as a single agent in this indication. The primary endpoint was the Disease Control Rate (DCR) at 6 weeks according to RECIST criteria. Secondary endpoints included DCR at 12 weeks, objective response rate (ORR) at 6 and 12 weeks, progression-free-survival (PFS), overall survival (OS), and safety profile. Fifty-eight patients received cetuximab as monotherapy. The median age was 83.2 (range, 47.4 to 96.1). The majority of patients was chemotherapy naïve. The median follow-up was 11.7 months (95% CI: 9.6-30.1). The DCR at 6 and 12 weeks was 87% and 70%, respectively. The ORR was 53% and 42%, respectively, at 6 and 12 weeks. The median PFS and OS were 9.7 months (95% CI: 4.8-43.4) and 17.5 months (95% CI: 9.4-43.1), respectively. Fifty-one patients (88%) experienced toxicity, and 67 adverse events related to cetuximab occurred. Most of them (84%) were grade 1 to 2. Our study shows that cetuximab is safe and efficient for the treatment of patients, even elderly ones, with advanced cSCC. These results indicate that cetuximab is a promising agent to test in new combinations, especially with immune checkpoint inhibitors such as anti–PD-1 agents.

Resume La tomographie par emission de positons au 18-fluorodesoxyglucose couplee a la tomodensitometrie ( 18 F-FDG TEP-TDM ou TEP-TDM) est devenue incontournable dans certains domaines de l’imagerie oncologique. Elle est parfois realisee, hors standard, au diagnostic ou dans le suivi des sarcomes. Materiels et methodes Nous avons evalue la pratique et l’impact de la TEP-TDM dans la prise en charge quotidienne des sarcomes de l’adulte a partir des dossiers consecutivement presentes en Reunion de concertation pluridisciplinaire « sarcome » pendant 10 mois. Resultats Sur 232 patients, 50 (21 %) avaient eu une TEP-TDM. La sensibilite et la specificite de la TEP-TDM etaient de 94,7 %, et 57,1 %, respectivement. La valeur de la SUV etait tres variable, y compris pour un sous-type histologique ou un grade donne. La TEP-TDM modifiait la strategie therapeutique dans 14 % des cas. Dans les cas ou des localisations extrapulmonaires sont suspectees pour certains sous-types particuliers de sarcomes, la TEP-TDM peut apporter des informations complementaires en raison de sa bonne sensibilite malgre sa faible specificite. Conclusion Compte tenu de la large predominance de la localisation pulmonaire comme site metastatique, un scanner thoracique en coupes fines est suffisant dans la plupart des cas pour le bilan d’extension. L’utilisation de la TEP-TDM dans le bilan des sarcomes de l’adulte doit etre discutee au cas par cas et sa place reste a preciser par des etudes complementaires.